Your session is about to expire
← Back to Search
Kinase Inhibitor
Targeted Therapy for Cancer
Phase 2
Waitlist Available
Led By Keith T Flaherty
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Any prior therapy, radiotherapy, or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better
Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy >= 4 weeks prior to start of treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Study Summary
This trial uses genomic testing to direct cancer treatment. Patients with cancer that has progressed after standard treatment or for which there is no agreed-upon treatment may benefit.
Who is the study for?
This trial is for patients with advanced solid tumors, lymphomas, or multiple myeloma that have worsened after standard treatment or lack a consensus treatment. Participants must be finished with previous treatments and recovered from their effects, not expect to conceive children, have an ECOG status of <=1 indicating they are relatively active, and meet specific health criteria including heart function and blood tests.Check my eligibility
What is being tested?
The MATCH trial is testing whether targeting therapy based on genetic abnormalities in the tumor cells can benefit patients whose cancer has progressed. It involves genetic testing to identify mutations or changes in the tumor's DNA and then matching patients with therapies specifically designed to target those genetic features.See study design
What are the potential side effects?
Potential side effects depend on the targeted therapy given but may include skin reactions, digestive issues, fatigue, liver problems, heart complications like QTc prolongation (a type of irregular heartbeat), allergic reactions to medication components, increased risk of infection due to immune system impact.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
It's been over 4 weeks since my last cancer treatment or major surgery, and any side effects are mild.
Select...
I finished treatment for brain cancer or metastases more than 4 weeks ago.
Select...
I have a confirmed diagnosis of cancer that needs treatment and has shown progression.
Select...
I can do light work and my doctor expects me to live at least 3 more months.
Select...
I stopped taking steroids at least a week ago and haven't taken any since.
Select...
I have had treatment for skin cancer that is not melanoma.
Select...
I have not had a hysterectomy or both ovaries removed and have had a menstrual cycle in the last 2 years.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Objective response rate (ORR)
Secondary outcome measures
6-month progression-free survival (PFS) rate
Overall survival (OS)
Progression free survival
Trial Design
38Treatment groups
Experimental Treatment
Group I: Subprotocol Z1M (LAG-3 expression >= 1%)Experimental Treatment4 Interventions
Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group II: Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)Experimental Treatment3 Interventions
Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group III: Subprotocol Z1K (AKT mutation)Experimental Treatment3 Interventions
Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group IV: Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)Experimental Treatment3 Interventions
Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Group V: Subprotocol Z1H (PTEN mutation)Experimental Treatment4 Interventions
Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group VI: Subprotocol Z1G (PTEN loss)Experimental Treatment4 Interventions
Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group VII: Subprotocol Z1F (PIK3CA mutation)Experimental Treatment7 Interventions
Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step.
Group VIII: Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)Experimental Treatment4 Interventions
Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group IX: Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)Experimental Treatment3 Interventions
Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group X: Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)Experimental Treatment3 Interventions
Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XI: Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)Experimental Treatment3 Interventions
Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XII: Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)Experimental Treatment3 Interventions
Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XIII: Subprotocol Y (Akt mutation)Experimental Treatment3 Interventions
Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XIV: Subprotocol X (DDR2 S768R, I638F, or L239R mutation)Experimental Treatment3 Interventions
Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XV: Subprotocol W (FGFR pathway aberrations)Experimental Treatment3 Interventions
Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XVI: Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)Experimental Treatment3 Interventions
Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Group XVII: Subprotocol U (NF2 inactivating mutation)Experimental Treatment4 Interventions
Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XVIII: Subprotocol T (SMO or PTCH1 mutation)Experimental Treatment3 Interventions
Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XIX: Subprotocol S2 (GNAQ or GNA11 mutation)Experimental Treatment3 Interventions
Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XX: Subprotocol S1 (NF1 mutation)Experimental Treatment3 Interventions
Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXI: Subprotocol R (BRAF fusion or BRAF non-V600 mutation)Experimental Treatment3 Interventions
Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXII: Subprotocol Q (HER2 amplification)Experimental Treatment4 Interventions
Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Group XXIII: Subprotocol P (PTEN loss)Experimental Treatment3 Interventions
Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXIV: Subprotocol N (PTEN mutation or deletion and PTEN expression)Experimental Treatment3 Interventions
Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXV: Subprotocol M (TSC1 or TSC2 mutation)Experimental Treatment3 Interventions
Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Group XXVI: Subprotocol L (mTOR mutation)Experimental Treatment3 Interventions
Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Group XXVII: Subprotocol K2 (FGFR mutation or fusion)Experimental Treatment7 Interventions
Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT or MRI, and tumor biopsy throughout the study.
Group XXVIII: Subprotocol K1 (FGFR amplification)Experimental Treatment7 Interventions
Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.
Group XXIX: Subprotocol J (HER2 amplification >= 7 copy numbers)Experimental Treatment9 Interventions
Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment.
Group XXX: Subprotocol I (PIK3CA mutation)Experimental Treatment3 Interventions
Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXXI: Subprotocol H (BRAF V600E/R/K/D mutation)Experimental Treatment5 Interventions
Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXXII: Subprotocol G (ROS1 translocation or inversion)Experimental Treatment3 Interventions
Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXXIII: Subprotocol F (ALK translocation)Experimental Treatment3 Interventions
Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXXIV: Subprotocol E (EGFR T790M or rare activating mutation)Experimental Treatment8 Interventions
Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or MUGA during screening, and biopsy and collection of blood samples on trial and at end of treatment.
Group XXXV: Subprotocol C2 (MET exon 14 deletion/mutation)Experimental Treatment3 Interventions
Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXXVI: Subprotocol C1 (MET amplification)Experimental Treatment3 Interventions
Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXXVII: Subprotocol B (HER2 activating mutation)Experimental Treatment4 Interventions
Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group XXXVIII: Subprotocol A (EGFR activating mutation)Experimental Treatment4 Interventions
Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trastuzumab Emtansine
2016
Completed Phase 3
~5630
Ipatasertib
2011
Completed Phase 3
~2320
Dasatinib
2012
Completed Phase 3
~2320
Defactinib
2013
Completed Phase 1
~60
Copanlisib
2016
Completed Phase 2
~130
Biospecimen Collection
2004
Completed Phase 2
~1730
Osimertinib
2017
Completed Phase 4
~1010
Echocardiography
2013
Completed Phase 4
~11670
Pertuzumab
2014
Completed Phase 3
~7500
Adavosertib
2015
Completed Phase 2
~570
Afatinib
2016
Completed Phase 4
~2340
Afatinib Dimaleate
2015
Completed Phase 1
~60
Binimetinib
2018
Completed Phase 3
~1100
Biopsy
2014
Completed Phase 4
~850
Relatlimab
2018
Completed Phase 2
~1110
Sapanisertib
2016
Completed Phase 2
~840
Sunitinib Malate
2008
Completed Phase 3
~3070
Taselisib
2014
Completed Phase 2
~2230
Capivasertib
2021
Completed Phase 1
~130
Dabrafenib
2011
Completed Phase 3
~4120
Dabrafenib Mesylate
2014
Completed Phase 2
~10
Erdafitinib
2017
Completed Phase 2
~150
Magnetic Resonance Imaging
2017
Completed Phase 3
~1190
Nivolumab
2014
Completed Phase 3
~4750
Computed Tomography
2017
Completed Phase 2
~2720
Trametinib
2014
Completed Phase 2
~1550
Palbociclib
2017
Completed Phase 3
~3760
Crizotinib
2014
Completed Phase 3
~2370
Trastuzumab
2014
Completed Phase 4
~5190
Vismodegib
2015
Completed Phase 4
~1880
Ulixertinib
2020
Completed Phase 1
~20
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
13,654 Previous Clinical Trials
40,926,701 Total Patients Enrolled
Keith T FlahertyPrincipal InvestigatorECOG-ACRIN Cancer Research Group
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- It's been over 4 weeks since my last cancer treatment or major surgery, and any side effects are mild.I finished treatment for brain cancer or metastases more than 4 weeks ago.I have started my menstrual periods.I do not have any of the excluded medical conditions or treatments.You have abnormal blood test results.My heart function is within the normal range.I have not had certain types of cancer before.I have a confirmed diagnosis of cancer that needs treatment and has shown progression.I can provide a tumor sample for testing.You must use effective birth control or avoid sex before and during the study, and for 4 months after the study ends. If you or your partner become pregnant during the study, tell your doctor right away.You can still participate if you have HIV, but you need to meet certain requirements.Patients must have certain blood and chemistry test results within a specific range.I am not taking any medications that are not allowed in this study.I can do light work and my doctor expects me to live at least 3 more months.I stopped taking steroids at least a week ago and haven't taken any since.I don't have conditions that could cause abnormal heart rhythms.My cancer has not responded to standard treatments, and no other effective options are available.I had an ECG test within the last 8 weeks and my heart meets the study's criteria.Requirements for the initial biopsy used to determine if you are eligible for the clinical trial.I have had treatment for skin cancer that is not melanoma.I have been cancer-free from another type for 5 years.I do not have any conditions that increase my risk of heart rhythm problems.I have not had a hysterectomy or both ovaries removed and have had a menstrual cycle in the last 2 years.
Research Study Groups:
This trial has the following groups:- Group 1: Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)
- Group 2: Subprotocol Z1M (LAG-3 expression >= 1%)
- Group 3: Subprotocol C2 (MET exon 14 deletion/mutation)
- Group 4: Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)
- Group 5: Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)
- Group 6: Subprotocol I (PIK3CA mutation)
- Group 7: Subprotocol A (EGFR activating mutation)
- Group 8: Subprotocol C1 (MET amplification)
- Group 9: Subprotocol B (HER2 activating mutation)
- Group 10: Subprotocol E (EGFR T790M or rare activating mutation)
- Group 11: Subprotocol K1 (FGFR amplification)
- Group 12: Subprotocol T (SMO or PTCH1 mutation)
- Group 13: Subprotocol F (ALK translocation)
- Group 14: Subprotocol P (PTEN loss)
- Group 15: Subprotocol H (BRAF V600E/R/K/D mutation)
- Group 16: Subprotocol L (mTOR mutation)
- Group 17: Subprotocol M (TSC1 or TSC2 mutation)
- Group 18: Subprotocol W (FGFR pathway aberrations)
- Group 19: Subprotocol G (ROS1 translocation or inversion)
- Group 20: Subprotocol J (HER2 amplification >= 7 copy numbers)
- Group 21: Subprotocol R (BRAF fusion or BRAF non-V600 mutation)
- Group 22: Subprotocol Z1F (PIK3CA mutation)
- Group 23: Subprotocol Q (HER2 amplification)
- Group 24: Subprotocol K2 (FGFR mutation or fusion)
- Group 25: Subprotocol Z1K (AKT mutation)
- Group 26: Subprotocol U (NF2 inactivating mutation)
- Group 27: Subprotocol N (PTEN mutation or deletion and PTEN expression)
- Group 28: Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)
- Group 29: Subprotocol S1 (NF1 mutation)
- Group 30: Subprotocol Y (Akt mutation)
- Group 31: Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)
- Group 32: Subprotocol S2 (GNAQ or GNA11 mutation)
- Group 33: Subprotocol X (DDR2 S768R, I638F, or L239R mutation)
- Group 34: Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)
- Group 35: Subprotocol Z1G (PTEN loss)
- Group 36: Subprotocol Z1H (PTEN mutation)
- Group 37: Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)
- Group 38: Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Lung Cancer Patient Testimony for trial: Trial Name: NCT02465060 — Phase 2
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What prior investigations have included Subprotocol R considerations of BRAF union or non-V600 mutation?
"Presently, 1594 clinical trials are underway to evaluate Subprotocol R (BRAF fusion or BRAF non-V600 mutation), 237 of those being in the last phase. Most studies for this therapy take place in Seattle, Washington but there exist 890 other sites running these experiments."
Answered by AI
What is the intake capacity for this clinical research?
"To fulfill the requirements of this trial, 6452 eligible participants must enroll. These patients can join from various medical facilities such as Saint Jude Medical Center in Fullerton, Colorado and Providence Saint Joseph Medical Center/Disney Family Cancer Center situated in Burbank, Idaho."
Answered by AI
Are there any vacancies for individuals interested in participating in this research?
"Affirmative. According to the data on clinicaltrials.gov, this medical trial is currently recruiting patients and has been since August 12th 2015. The last update was made on November 30th 2022, with a total of 6452 participants needed from across 100 locations."
Answered by AI
How many healthcare establishments are administering this experiment?
"This research is recruiting patients from Saint Jude Medical Center in Fullerton, Colorado, Providence Saint Joseph Medical Center/Disney Family Cancer Center in Burbank, Idaho and Southwest Oncology PC in Durango, Connecticut as well as other 100 sites."
Answered by AI
What medical conditions are typically treated through Subprotocol R (BRAF fusion or BRAF non-V600 mutation)?
"Subprotocol R (BRAF fusion or BRAF non-V600 mutation) is primarily used to address renal failure but can also be applied for the management of metastatic basal cell carcinoma, inoperable melanoma, and squamous cell carcinomas."
Answered by AI
Is Subprotocol R (BRAF fusion or BRAF non-V600 mutation) sanctioned by the FDA?
"Subprotocol R of this trial (BRAF fusion or BRAF non-V600 mutation) was assessed at a score 2 on the safety scale, as there is clinical data confirming its safety but no evidence to back up efficacy yet."
Answered by AI
Who else is applying?
What state do they live in?
Connecticut
Virginia
Texas
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
3+
What site did they apply to?
Carle Cancer Center
NYP/Weill Cornell Medical Center
Legacy Good Samaritan Hospital and Medical Center
Other
Why did patients apply to this trial?
Well I had a cancerous tumor removed June 2022, and received 6 rounds of chemo between August and November, stage 3a. But in January the CT scan was clear and the genetic blood test was clear and so I was cancer free. However in May of this a prostate biopsy was done and have fairly advanced cancer that has likely spread outside of the prostate. I have appointments with oncology and urology in the next couple of weeks to hopefully begin to get some clarification on what treatment they want to recommend.
PatientReceived 1 prior treatment
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger